A preclinical study comparing an anti‐Ang2 antibody (REGN910) with an antagonistic anti‐Tie2 antibody (REGN1376) reported similar efficacy in six out of seven tumor models evaluated (Adler et al,2014). This evidence concerns the gene TEK and neoplasm.